Showing 241 - 260 results of 6,447 for search 'significantly ((((((largest decrease) OR (we decrease))) OR (greatest decrease))) OR (nn decrease))', query time: 0.61s Refine Results
  1. 241

    Data for the G7 countries in 2022. by Luis Alberiko Gil-Alana (14659817)

    Published 2024
    “…The results indicate that only France displays a significant negative trend and thus a continuous decrease in the level of alcohol consumption. …”
  2. 242

    Time series plots: Alcohol consumption. by Luis Alberiko Gil-Alana (14659817)

    Published 2024
    “…The results indicate that only France displays a significant negative trend and thus a continuous decrease in the level of alcohol consumption. …”
  3. 243

    Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    “…While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …”
  4. 244
  5. 245
  6. 246
  7. 247

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  8. 248
  9. 249
  10. 250

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  11. 251

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  12. 252

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  13. 253
  14. 254

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260